Egiptus - inglise - EDA (Egyptian Drug Authority)

egyptian pharmaceutical trading company - injection - 1 mg

Jaapan - inglise - すりの適正使用協議会 RAD-AR Council, Japan

nippon kayaku - vincristine sulfate - injection

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - vinblastine sulfate, quantity: 10 mg - injection, powder for - excipient ingredients: - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) velbe is indicated in the treatment of the following: frequently responsive malignancies: generalised hodgkin's disease (stage iii and iv; ann arbor modification of rye staging system) lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated); histiocytic lymphoma; mycosis fungoides (advanced stages);. advanced carcinoma of the testis; kaposi's sarcoma,; letterer-siwe disease (histiocytosis x) ii. less frequently responsive malignancies:choriocarcinoma resistant to other chemotherapeutic agents; carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy. current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - vincristine - solution for injection - 1 milligram

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - vincristine - solution for injection - 2 milligram

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - vincristine sulfate - solution for injection - 1mg/1ml

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

genentech, inc. - rituximab (unii: 4f4x42syq6) (rituximab - unii:4f4x42syq6) - rituximab 10 mg in 1 ml - rituxan is indicated for the treatment of adult patients with: - relapsed or refractory, low-grade or follicular, cd20-positive, b-cell nhl as a single agent. - previously untreated follicular, cd20-positive, b-cell nhl in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. - non-progressing (including stable disease), low-grade, cd20-positive, b-cell nhl as a single agent after first-line cyclophosphamide, vincristine, and prednisone (cvp) chemotherapy. - previously untreated diffuse large b-cell, cd20-positive nhl in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (chop) or other anthracycline-based chemotherapy regimens. rituxan is indicated for the treatment of pediatric patients aged 6 months and older with: - previously untreated, advanced stage, cd20-positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl), burkitt-like lymph

Kanada - inglise - Health Canada

novopharm limited - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

Kanada - inglise - Health Canada

omega laboratories limited - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

Kanada - inglise - Health Canada

strides pharma canada inc - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents